A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
